No Data
CLSA PREMIUM received a discount of approximately 33.57% from Beijing Tongrentang (Cayman) Limited for the full purchase offer.
CLSA PREMIUM (06877) and the offeror Beijing Tongrentang (Cayman) Ltd jointly announced that on February 18, 2025, the offeror completed the acquisition of approximately 0.813 billion shares from CITIC SEC International Ltd, accounting for 40% of the company's total issued share capital as of the date of this joint announcement, for a total consideration of 97.994 million Hong Kong dollars (equivalent to about 0.1205 Hong Kong dollars per share sold). Following the completion and as of the date of this joint announcement, the offeror and its concert parties (including the seller) own about 1.2 billion shares (approximately 59.03% of the company's total issued share capital).
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, with the reduction slightly exceeding expectations.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Tong Ren Tang Technologies Renews Trademark Licence Contract With Tong Ren Tang Chinese Medicine
